Mark Pepys, FMedSci, FRS | oneAMYLOIDOSISvoice

Mark Pepys, FMedSci, FRS

Wolfson Drug Discovery Unit
Centre for Amyloidosis & Acute Phase Proteins
University College London
Rowland Hill Street
London, United Kingdom
Mark Pepys is a Director of Wolfson Drug Discovery Unit Centre for Amyloidosis & Acute Phase Proteins and Clinical Research Associate in Department of Medicine at University College London (UCL). He is a physician and immunologist whose work on blood proteins has elucidated mechanisms of disease, identified new targets for treatment and led to improved diagnosis and treatments.
He invented a unique, non-invasive scan for diagnosis and monitoring of patients with amyloidosis, a fatal disease caused by accumulation of abnormal protein fibres in the tissues. His work has greatly improved understanding, management and outcome of the disease, and he founded the world-leading National Amyloidosis Centre, which serves patients from the United Kingdom and many from abroad.
Mark has also designed new therapeutic approaches for amyloidosis and Alzheimer’s disease. His treatment for amyloidosis is being developed by GlaxoSmithKline in collaboration with the Wolfson Drug Discovery Unit at UCL, and its clinical trial is providing positive results. 
Representative Publications:


The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.